Patients' assessment of adalimumab self-injection for Crohn's disease

A multicenter questionnaire survey (The PEARL survey)

Fumihito Hirai, Kenji Watanabe, Takayuki Matsumoto, Masaki Iimuro, Noriko Kamata, Naoya Kubokura, Motohiro Esaki, Hirokazu Yamagami, Yutaka Yano, Nobuyuki Hida, Shiro Nakamura, Toshiyuki Matsui

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/aims: Adalimumab (ADA) is a self-injectable anti-tumor necrosis factor-α antibody used for treating Crohn's disease (CD). Although self-injecting ADA may be convenient for patients, few reports have assessed patients receiving ADA self-injection therapy. Methodology: We conducted a questionnaire survey involving outpatients on ADA self-injection therapy at four university hospitals. We analyzed the degree of satisfaction with and adherence to the self-injection therapy and performed sub-analyses. Results: Responses were obtained from 124 patients. Before treatment initiation, 38% patients replied that they were unwilling to accept the self-injection therapy. However, after treatment initiation, 75% patients were satisfied with the treatment. 66 patients previously treated with infliximab (IFX), the degree of treatment satisfaction was significantly higher in patients who felt burdened to the time required for IFX infusion than in those who had not felt burdened (P < 0.05). Patient adherence to ADA was high (85%). Multivariate analysis regarding adherence revealed that duration of disease (OR, 0.99), degree of treatment efficacy satisfaction (OR, 13.42), and schedule registration (OR, 7.95) were significant. Safety assessment results were within the range of those already reported. Conclusions: ADA self-injection was thought to have good adherence and a safe administration method according to patients' assessments.

Original languageEnglish
Pages (from-to)1654-1660
Number of pages7
JournalHepato-gastroenterology
Volume61
Issue number134
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Crohn Disease
Injections
Therapeutics
Adalimumab
Surveys and Questionnaires
Patient Compliance
Appointments and Schedules
Outpatients
Multivariate Analysis
Tumor Necrosis Factor-alpha
Safety
Antibodies

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Hirai, F., Watanabe, K., Matsumoto, T., Iimuro, M., Kamata, N., Kubokura, N., ... Matsui, T. (2014). Patients' assessment of adalimumab self-injection for Crohn's disease: A multicenter questionnaire survey (The PEARL survey). Hepato-gastroenterology, 61(134), 1654-1660. https://doi.org/10.5754/hge14471

Patients' assessment of adalimumab self-injection for Crohn's disease : A multicenter questionnaire survey (The PEARL survey). / Hirai, Fumihito; Watanabe, Kenji; Matsumoto, Takayuki; Iimuro, Masaki; Kamata, Noriko; Kubokura, Naoya; Esaki, Motohiro; Yamagami, Hirokazu; Yano, Yutaka; Hida, Nobuyuki; Nakamura, Shiro; Matsui, Toshiyuki.

In: Hepato-gastroenterology, Vol. 61, No. 134, 01.01.2014, p. 1654-1660.

Research output: Contribution to journalArticle

Hirai, F, Watanabe, K, Matsumoto, T, Iimuro, M, Kamata, N, Kubokura, N, Esaki, M, Yamagami, H, Yano, Y, Hida, N, Nakamura, S & Matsui, T 2014, 'Patients' assessment of adalimumab self-injection for Crohn's disease: A multicenter questionnaire survey (The PEARL survey)', Hepato-gastroenterology, vol. 61, no. 134, pp. 1654-1660. https://doi.org/10.5754/hge14471
Hirai, Fumihito ; Watanabe, Kenji ; Matsumoto, Takayuki ; Iimuro, Masaki ; Kamata, Noriko ; Kubokura, Naoya ; Esaki, Motohiro ; Yamagami, Hirokazu ; Yano, Yutaka ; Hida, Nobuyuki ; Nakamura, Shiro ; Matsui, Toshiyuki. / Patients' assessment of adalimumab self-injection for Crohn's disease : A multicenter questionnaire survey (The PEARL survey). In: Hepato-gastroenterology. 2014 ; Vol. 61, No. 134. pp. 1654-1660.
@article{caa89186fd0d4015aa92fda3629f1ef2,
title = "Patients' assessment of adalimumab self-injection for Crohn's disease: A multicenter questionnaire survey (The PEARL survey)",
abstract = "Background/aims: Adalimumab (ADA) is a self-injectable anti-tumor necrosis factor-α antibody used for treating Crohn's disease (CD). Although self-injecting ADA may be convenient for patients, few reports have assessed patients receiving ADA self-injection therapy. Methodology: We conducted a questionnaire survey involving outpatients on ADA self-injection therapy at four university hospitals. We analyzed the degree of satisfaction with and adherence to the self-injection therapy and performed sub-analyses. Results: Responses were obtained from 124 patients. Before treatment initiation, 38{\%} patients replied that they were unwilling to accept the self-injection therapy. However, after treatment initiation, 75{\%} patients were satisfied with the treatment. 66 patients previously treated with infliximab (IFX), the degree of treatment satisfaction was significantly higher in patients who felt burdened to the time required for IFX infusion than in those who had not felt burdened (P < 0.05). Patient adherence to ADA was high (85{\%}). Multivariate analysis regarding adherence revealed that duration of disease (OR, 0.99), degree of treatment efficacy satisfaction (OR, 13.42), and schedule registration (OR, 7.95) were significant. Safety assessment results were within the range of those already reported. Conclusions: ADA self-injection was thought to have good adherence and a safe administration method according to patients' assessments.",
author = "Fumihito Hirai and Kenji Watanabe and Takayuki Matsumoto and Masaki Iimuro and Noriko Kamata and Naoya Kubokura and Motohiro Esaki and Hirokazu Yamagami and Yutaka Yano and Nobuyuki Hida and Shiro Nakamura and Toshiyuki Matsui",
year = "2014",
month = "1",
day = "1",
doi = "10.5754/hge14471",
language = "English",
volume = "61",
pages = "1654--1660",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "134",

}

TY - JOUR

T1 - Patients' assessment of adalimumab self-injection for Crohn's disease

T2 - A multicenter questionnaire survey (The PEARL survey)

AU - Hirai, Fumihito

AU - Watanabe, Kenji

AU - Matsumoto, Takayuki

AU - Iimuro, Masaki

AU - Kamata, Noriko

AU - Kubokura, Naoya

AU - Esaki, Motohiro

AU - Yamagami, Hirokazu

AU - Yano, Yutaka

AU - Hida, Nobuyuki

AU - Nakamura, Shiro

AU - Matsui, Toshiyuki

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background/aims: Adalimumab (ADA) is a self-injectable anti-tumor necrosis factor-α antibody used for treating Crohn's disease (CD). Although self-injecting ADA may be convenient for patients, few reports have assessed patients receiving ADA self-injection therapy. Methodology: We conducted a questionnaire survey involving outpatients on ADA self-injection therapy at four university hospitals. We analyzed the degree of satisfaction with and adherence to the self-injection therapy and performed sub-analyses. Results: Responses were obtained from 124 patients. Before treatment initiation, 38% patients replied that they were unwilling to accept the self-injection therapy. However, after treatment initiation, 75% patients were satisfied with the treatment. 66 patients previously treated with infliximab (IFX), the degree of treatment satisfaction was significantly higher in patients who felt burdened to the time required for IFX infusion than in those who had not felt burdened (P < 0.05). Patient adherence to ADA was high (85%). Multivariate analysis regarding adherence revealed that duration of disease (OR, 0.99), degree of treatment efficacy satisfaction (OR, 13.42), and schedule registration (OR, 7.95) were significant. Safety assessment results were within the range of those already reported. Conclusions: ADA self-injection was thought to have good adherence and a safe administration method according to patients' assessments.

AB - Background/aims: Adalimumab (ADA) is a self-injectable anti-tumor necrosis factor-α antibody used for treating Crohn's disease (CD). Although self-injecting ADA may be convenient for patients, few reports have assessed patients receiving ADA self-injection therapy. Methodology: We conducted a questionnaire survey involving outpatients on ADA self-injection therapy at four university hospitals. We analyzed the degree of satisfaction with and adherence to the self-injection therapy and performed sub-analyses. Results: Responses were obtained from 124 patients. Before treatment initiation, 38% patients replied that they were unwilling to accept the self-injection therapy. However, after treatment initiation, 75% patients were satisfied with the treatment. 66 patients previously treated with infliximab (IFX), the degree of treatment satisfaction was significantly higher in patients who felt burdened to the time required for IFX infusion than in those who had not felt burdened (P < 0.05). Patient adherence to ADA was high (85%). Multivariate analysis regarding adherence revealed that duration of disease (OR, 0.99), degree of treatment efficacy satisfaction (OR, 13.42), and schedule registration (OR, 7.95) were significant. Safety assessment results were within the range of those already reported. Conclusions: ADA self-injection was thought to have good adherence and a safe administration method according to patients' assessments.

UR - http://www.scopus.com/inward/record.url?scp=84906966198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906966198&partnerID=8YFLogxK

U2 - 10.5754/hge14471

DO - 10.5754/hge14471

M3 - Article

VL - 61

SP - 1654

EP - 1660

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 134

ER -